全文获取类型
收费全文 | 270篇 |
免费 | 3篇 |
专业分类
儿科学 | 51篇 |
妇产科学 | 11篇 |
基础医学 | 20篇 |
临床医学 | 16篇 |
内科学 | 119篇 |
神经病学 | 29篇 |
特种医学 | 1篇 |
外科学 | 3篇 |
综合类 | 2篇 |
预防医学 | 5篇 |
眼科学 | 8篇 |
药学 | 7篇 |
肿瘤学 | 1篇 |
出版年
2021年 | 2篇 |
2020年 | 3篇 |
2019年 | 1篇 |
2018年 | 1篇 |
2017年 | 4篇 |
2016年 | 1篇 |
2015年 | 2篇 |
2014年 | 1篇 |
2013年 | 5篇 |
2012年 | 9篇 |
2011年 | 9篇 |
2010年 | 5篇 |
2009年 | 3篇 |
2008年 | 19篇 |
2007年 | 21篇 |
2006年 | 17篇 |
2005年 | 11篇 |
2004年 | 13篇 |
2003年 | 19篇 |
2002年 | 16篇 |
2001年 | 21篇 |
2000年 | 15篇 |
1999年 | 20篇 |
1996年 | 2篇 |
1994年 | 2篇 |
1993年 | 1篇 |
1992年 | 6篇 |
1991年 | 5篇 |
1990年 | 2篇 |
1989年 | 6篇 |
1988年 | 2篇 |
1986年 | 4篇 |
1985年 | 6篇 |
1984年 | 3篇 |
1983年 | 2篇 |
1982年 | 1篇 |
1931年 | 1篇 |
1929年 | 1篇 |
1925年 | 1篇 |
1924年 | 1篇 |
1923年 | 2篇 |
1920年 | 1篇 |
1918年 | 1篇 |
1911年 | 1篇 |
1906年 | 1篇 |
1901年 | 1篇 |
1900年 | 1篇 |
1897年 | 1篇 |
排序方式: 共有273条查询结果,搜索用时 15 毫秒
1.
2.
Straus Kehrer Hofmeier Schmitz Levinger A. W. Fischer Warsow Becker W. Heubner Schübel Koenigsfeld Deusch Grassheim J. Strasburger Eisner-Behrend H. Hirschfeld H. Von Kutschera Christeller Versé Pfaundler Gottschalk Sperling Freudenberg Sellheim Jonas Dietrich O. Wiener Mendel Fischer 《Journal of molecular medicine (Berlin, Germany)》1925,4(32):1561-1566
Ohne Zusammenfassung 相似文献
3.
Petersen Weil W. Heubner Starkenstein Oppenheimer Starkenstein Christeller Frischen Herzfeld Kleinschmidt Deusch W. V. Simon Eckstein Deusch Magnus-Alsleben Peiper Peiper Becker I. Strasburger A. W. Fischer Schlesinger Deusch Eisner-Behrend Hirschfeld H. Hirschfeld Christeller Staub Griesbach Sperling C. Posner M. Rosenberg Schübel M. Rosenberg Eisner Reiter Sperling Dietrich Jonas Schrader 《Journal of molecular medicine (Berlin, Germany)》1924,3(34):1548-1554
4.
J D Veldhuis M Bidlingmaier S M Anderson Z Wu C J Strasburger 《The Journal of clinical endocrinology and metabolism》2001,86(7):3304-3310
The present clinical study implements a novel interventional strategy of short-term profound and selective blockade of GH receptors to reduce plasma insulin-like growth factor I (IGF-I) concentrations reversibly in healthy eumetabolic adults. Thereby, we examine the feedback role of systemic IGF-I on GH secretion without introducing the complex metabolic disarray that can otherwise accompany secondary IGF-I deprivation. To this end, we sampled blood at 10-min intervals for 10 h overnight in 8 men (aged 19-46 yr) and 4 women (aged 19-39 yr) to quantitate endogenous GH secretion and half-life 72 h after the prospective, randomly ordered, double blind, and within-subject cross-over administration of pegvisomant (1 mg/kg) or saline (0.5 mL) sc. Pegvisomant is an oligopegylated recombinant human GH peptide mutated to antagonize GH receptor-dependent signaling. Statistical analyses of paired plasma IGF-I concentrations and deconvolution-based quantitation of pulsatile GH secretion revealed that GH receptor blockade 1) suppressed fasting total IGF-I concentrations by 31%, viz. from (mean +/- SEM) 276 +/- 42 (placebo) to 190 +/- 20 microg/L (pegvisomant; P = 0.006) 84 h after drug injection; 2) increased the 10-h mean serum GH concentration by 71% from 1.4 +/- 0.33 (placebo) to 2.4 +/- 0.58 (pegvisomant; P = 0.024); 3) augmented the amplitude of underlying GH secretory bursts by 2.1-fold (i.e. from 0.13 +/- 0.032 to 0.27 +/- 0.076 microg/L.min; P = 0.0088); and 4) elevated the basal/nonpulsatile rate of GH secretion by 2.5-fold (from 2.3 +/- 0.77 to 5.07 +/- 1.8 microg/L.10 h; P = 0.022). The rise in the amplitude of GH secretory bursts correlated with the fall in plasma IGF-I concentrations (r = 0.603; P = 0.038). In contrast, IGF-I depletion did not alter GH secretory pulse frequency, half-duration, interpulse interval, percentage of pulsatile GH release, or half-life of endogenous GH. In summary, selective short-term reduction of systemic IGF-I concentrations in healthy eumetabolic adults drives GH secretion via the specific bipartite neuroregulatory mechanism of amplified GH secretory burst amplitude and elevated basal/nonpulsatile GH release. Endogenous GH half-life and frequency-related features of pulsatile GH secretion are not measurably affected, thus identifying a highly distinctive mode of IGF-I feedback-dependent control of GH output. As the increment in GH secretory burst amplitude correlated with the decrement in plasma IGF-I concentrations, we infer that variations in circulating IGF-I availability within the adult midphysiological range can influence pulsatile and basal GH production by way of negative feedback. Based on data in experimental animals, we speculate that the negative feedback actions of systemic IGF-I on GH secretion are mediated via increased hypothalamic somatostatin release, decreased GHRH (or GH-releasing peptide) secretion, and/or suppressed pituitary GH biosynthesis. 相似文献
5.
Diagnosis and treatment of acromegaly complications 总被引:4,自引:0,他引:4
Giustina A Casanueva FF Cavagnini F Chanson P Clemmons D Frohman LA Gaillard R Ho K Jaquet P Kleinberg DL Lamberts SW Lombardi G Sheppard M Strasburger CJ Vance ML Wass JA Melmed S;Pituitary Society the European Neuroendocrine Association 《Journal of endocrinological investigation》2003,26(12):1242-1247
The Pituitary Society in conjunction with the European Neuroendocrine Association held a consensus workshop to develop guidelines for diagnosis and treatment of the co-morbid complications of acromegaly. Fifty nine pituitary specialists (endocrinologists, neurosurgeons and cardiologists) assessed the current published literature on acromegaly complications in light of recent advances in maintaining tight therapeutic control of GH hypersecretion. The impact of elevated GH levels on cardiovascular disease, hypertension, diabetes, sleep apnea, colon polyps, bone disease, reproductive disorders, and neuropsychologic complications were considered. Guidelines are proposed for effective management of these complications in the context of overall acromegaly control. When appropriate, requirements for prospective evidence-based studies and surveillance database development are enunciated. Effective management of co-morbid acromegaly complications will lead to improved morbidity and mortality in acromegaly. 相似文献
6.
Development and psychometric properties of a disease-specific quality of life questionnaire for adult patients with growth hormone deficiency 总被引:2,自引:0,他引:2
Herschbach P Henrich G Strasburger CJ Feldmeier H Marín F Attanasio AM Blum WF 《European journal of endocrinology / European Federation of Endocrine Societies》2001,145(3):255-265
BACKGROUND: Adults with growth hormone (GH) deficiency (GHD) may experience physical and psychological disturbances, which can affect their quality of life (QOL). OBJECTIVES: To develop and validate a disease-specific module from the previously published QOL measure Questions on Life Satisfaction Modules (QLS(M)): the QLS(M)-H that specifically addressed the needs of patients with hypopituitarism. A second aim was for the questionnaire to be applicable across different cultural backgrounds in order to evaluate the efficacy of therapy in large, international clinical trials, thus providing additional clinical endpoints for these studies. DESIGN: A preliminary German language version of the QLS(M)-H was developed from 26 semi-structured interviews of adults with GHD. The questionnaire was then independently translated into five other languages and applied in open, non-controlled, multicentre, longitudinal studies to patient (n=717) and normative populations (n=2700). METHODS: A revised, nine-item version of the questionnaire was developed, based on previously defined criteria, and was evaluated for reliability and validity. Sensitivity to detect changes after GH replacement was also assessed. RESULTS: The 16 items of the preliminary questionnaire were reduced to nine items on the basis of the correlation of items/factors from initial patient interviews. Psychometric analysis revealed the reliability of the nine-item scale. The Cronbach's alpha scores ranged from 0.81 to 0.89 and the test-retest correlations ranged from 0.76 to 0.88, all of which indicate reliability over time. Mean scores increased significantly during GH replacement therapy, with observed changes greater than those seen with the non-specific modules of the QLS(M), indicating the sensitivity of the scale. CONCLUSIONS: The QLS(M)-H questionnaire is concise, easy to complete, and can be effectively applied across different cultural backgrounds. Psychometric evaluation of the questionnaire reveals that it is a valid, reliable and sensitive tool useful for assessing impaired life satisfaction in adult patients with GHD and also for monitoring the efficacy of GH therapy. 相似文献
7.
Kreitschmann-Andermahr Ilonka Siegel Sonja Unger Nicole Streetz-van der Werf Christine Karges Wolfram Schilbach Katharina Schröder Bernadette Szybowicz Janine Sauerwald Janina Zopf Kathrin Grzywotz Agnieszka Bidlingmaier Martin Sommer Heide Strasburger Christian J. 《Pituitary》2020,23(5):479-487
Pituitary - While reasons for non-adherence in children requiring growth hormone (GH) replacement (GH-Rx) are well researched, few studies have investigated adherence in adult GH deficient... 相似文献
8.
9.
10.
Fazeli M Zarkesh-Esfahani H Wu Z Maamra M Bidlingmaier M Pockley AG Watson P Matarese G Strasburger CJ Ross RJ 《Journal of immunological methods》2006,312(1-2):190-200
Nutritional status has a major impact on the immune response and this is in part mediated by leptin, a pro-inflammatory cytokine. Preliminary data suggest that antagonism of leptin may offer a therapeutic approach for the treatment of some inflammatory disorders. We have tested monoclonal antibodies (mAbs) to the human leptin receptor (ObR) for antagonist activity using a leptin signalling bioassay. We identified a mAb, 9F8, which demonstrated dose-dependent antagonist activity in the leptin bioassay. Specificity of the mAb for ObR was confirmed using a plate binding assay. The 9F8 mAb displaced leptin binding to human ObR and enzymatically generated Fab fragments of 9F8 retained antagonist activity. Therefore the Fab fragment of 9F8 was cloned and recombinant 9F8 Fab (rFab) was purified from E. coli periplasmic fraction using a C-terminal His tag. Purified 9F8 rFab bound to human ObR and exhibited leptin antagonist activity. In vitro studies demonstrated that the 9F8 mAb inhibited leptin induced TNF-alpha production from human monocytes and anti-CD3 mAb induced proliferation of human T cells in PBMC culture. In conclusion, this study has identified a mAb to the human leptin receptor which inhibits leptin signalling and acts as a leptin antagonist in vitro. 相似文献